Abstract
The gestational period, spanning approximately 40 weeks from fertilization to birth, is pivotal in human reproduction. Monitoring the health of pregnant women and newborns during this period involves systematic prenatal and postpartum examinations, guided by indicators established under the national medical insurance system, collectively termed gestational phenotypes. However, our understanding of the genetic basis of these phenotypes and their intricate relationship with maternal long-term health outcomes remain markedly limited. We conducted comprehensive genetic investigations into 122 gestational phenotypes among 121,579 Chinese pregnancies. These phenotypes included anthropometric metrics, comprehensive blood biomarker measurements, and common gestational complications and outcomes. We identified 3,845 genetic loci, 1,385 of which are novel. Our analyses revealed gestation-specific genetic effects, ranging from proportion 0% to 100% for 23 phenotypes, highlighting genes and pathways predominantly enriched in response to hormones, growth and immune function. Longitudinal trajectory genome-wide association study (GWAS) analyses of repeated measures across 24 complete blood cell phenotypes revealed that 17.8% of the genetic variants exhibited significant interactions with gestational timing across five gestational and postpartum periods. Two-sample univariable and multivariable Mendelian Randomization (MR) analyses of 220 mid- and old-age phenotypes suggested causal associations between gestational phenotypes and the risk of chronic diseases in later life. These findings provide initial insights into the genetic foundations of human gestational phenotypes and their relationship with long-term health, laying a basis for advanced population health during gestation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by Shenzhen Basic Research Foundation (20220818100717002), Guangdong Basic and Applied Basic Research Foundation (2022B1515120080, 2020A1515110859), National Natural Science Foundation of China (31900487), and the Shenzhen Health Elite Talent Training Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Ethics Committee of the School of Public Health (Shenzhen), Sun Yat-sen University, Longgang District Maternity and Child Healthcare Hospital of Shenzhen City, and Shenzhen Baoan Women's and Children's Hospital. Data collection was approved by the Human Genetic Resources Administration of China (HGRAC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Full GWAS summary statistics can be accessed through the China National Center for Bioinformation, with approval from the Human Genetic Resources Administration of China (HGRAC).
